Literature DB >> 3896488

Structure of the amino acid-containing capsular polysaccharide (K54 antigen) from Escherichia coli O6:K54:H10.

P Hofmann, B Jann, K Jann.   

Abstract

The structure of the K54-antigenic polysaccharide (K54 antigen) of Escherichia coli O6:K54:H10 was elucidated by determination of the composition, 1H- and 13C-n.m.r. spectroscopy, periodate oxidation, and a study of the oligosaccharides obtained by partial hydrolysis with acid. The K54 polysaccharide consists of----3)-beta-D-glucosyluronic acid-(1----3)-alpha-L-rhamnosyl-(1----repeating-units. Of the glucuronic acid residues, approximately 85% are substituted in the ratio 9:1 with L-threonine and L-serine amidically linked to the carboxyl group. The K54 polysaccharide has a molecular weight of approximately 160,000, corresponding to approximately 380 repeating-units.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3896488     DOI: 10.1016/0008-6215(85)90025-4

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  4 in total

1.  TnphoA-mediated disruption of K54 capsular polysaccharide genes in Escherichia coli confers serum sensitivity.

Authors:  T A Russo; M C Moffitt; C H Hammer; M M Frank
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

2.  Synthesis of glycuronamides of amino acids, constituents of microbial polysaccharides and their conversion into neoglycoconjugates of copolymer type.

Authors:  A Y Chernyak; G V Sharma; L O Kononov; P R Krishna; A V Rao; N K Kochetkov
Journal:  Glycoconj J       Date:  1991-04       Impact factor: 2.916

3.  An extraintestinal, pathogenic isolate of Escherichia coli (O4/K54/H5) can produce a group 1 capsule which is divergently regulated from its constitutively produced group 2, K54 capsular polysaccharide.

Authors:  T A Russo; G Singh
Journal:  J Bacteriol       Date:  1993-12       Impact factor: 3.490

4.  Crossreactions of Escherichia coli K and O polysaccharides in antipneumococcal and anti-Salmonella sera.

Authors:  M Heidelberger; K Jann; B Jann
Journal:  J Exp Med       Date:  1985-10-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.